Joshua Thurman
Concepts (636)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 47 | 2026 | 326 | 12.450 |
Why?
| | Complement Activation | 69 | 2026 | 412 | 11.940 |
Why?
| | Kidney Diseases | 26 | 2026 | 428 | 9.020 |
Why?
| | Complement Pathway, Alternative | 36 | 2025 | 123 | 6.270 |
Why?
| | Complement Inactivating Agents | 18 | 2026 | 78 | 5.750 |
Why?
| | Complement Factor H | 19 | 2025 | 81 | 5.700 |
Why?
| | Kidney Glomerulus | 18 | 2026 | 129 | 4.860 |
Why?
| | Kidney | 31 | 2023 | 1498 | 3.820 |
Why?
| | Reperfusion Injury | 15 | 2019 | 300 | 3.610 |
Why?
| | Complement Factor B | 25 | 2023 | 106 | 3.560 |
Why?
| | Glomerulonephritis | 9 | 2023 | 46 | 3.480 |
Why?
| | Autoimmune Diseases | 10 | 2025 | 467 | 2.930 |
Why?
| | Immunoglobulin M | 10 | 2025 | 284 | 2.900 |
Why?
| | Complement C3 | 25 | 2023 | 195 | 2.710 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 8 | 2026 | 23 | 2.370 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 43 | 2.360 |
Why?
| | Acute Kidney Injury | 13 | 2024 | 866 | 2.280 |
Why?
| | Graft Rejection | 10 | 2025 | 516 | 2.210 |
Why?
| | Kidney Tubules | 8 | 2024 | 117 | 1.760 |
Why?
| | Receptor, Anaphylatoxin C5a | 7 | 2024 | 35 | 1.660 |
Why?
| | Nephrotic Syndrome | 3 | 2026 | 44 | 1.620 |
Why?
| | Receptors, Complement | 12 | 2026 | 126 | 1.610 |
Why?
| | Glomerulonephritis, Membranoproliferative | 7 | 2026 | 29 | 1.540 |
Why?
| | Lupus Nephritis | 7 | 2021 | 67 | 1.530 |
Why?
| | Endothelial Cells | 8 | 2026 | 876 | 1.520 |
Why?
| | Animals | 112 | 2026 | 38107 | 1.430 |
Why?
| | Antibodies | 4 | 2024 | 400 | 1.430 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 11 | 1.420 |
Why?
| | Kidney Transplantation | 10 | 2025 | 735 | 1.410 |
Why?
| | Annexin A2 | 2 | 2025 | 15 | 1.370 |
Why?
| | Mice | 78 | 2026 | 18297 | 1.360 |
Why?
| | Mice, Knockout | 36 | 2026 | 3125 | 1.340 |
Why?
| | Complement C3d | 10 | 2025 | 67 | 1.340 |
Why?
| | Inflammation | 17 | 2025 | 2919 | 1.280 |
Why?
| | Complement C3b | 4 | 2023 | 30 | 1.270 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 589 | 1.260 |
Why?
| | Epitopes | 8 | 2023 | 479 | 1.220 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 829 | 1.110 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 39 | 1.090 |
Why?
| | Disease Models, Animal | 31 | 2025 | 4580 | 1.090 |
Why?
| | Antibodies, Monoclonal | 17 | 2025 | 1512 | 1.070 |
Why?
| | Epithelial Cells | 10 | 2024 | 1119 | 1.070 |
Why?
| | Mice, Inbred C57BL | 45 | 2025 | 6034 | 1.020 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 15 | 1.020 |
Why?
| | Humans | 109 | 2026 | 146342 | 0.960 |
Why?
| | Contrast Media | 4 | 2018 | 493 | 0.940 |
Why?
| | Complement C5a | 7 | 2024 | 54 | 0.940 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 18 | 0.910 |
Why?
| | Antibodies, Anticardiolipin | 1 | 2025 | 7 | 0.900 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 19 | 0.880 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.870 |
Why?
| | Delayed Graft Function | 1 | 2025 | 56 | 0.870 |
Why?
| | Infliximab | 1 | 2025 | 107 | 0.860 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 345 | 0.860 |
Why?
| | Organ Transplantation | 2 | 2019 | 244 | 0.840 |
Why?
| | Biomarkers | 19 | 2025 | 4340 | 0.790 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 952 | 0.760 |
Why?
| | Glomerulonephritis, IGA | 2 | 2026 | 14 | 0.760 |
Why?
| | Nephritis | 2 | 2013 | 22 | 0.750 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 70 | 0.750 |
Why?
| | Immunoglobulin G | 12 | 2025 | 901 | 0.740 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 241 | 0.740 |
Why?
| | Complement Membrane Attack Complex | 7 | 2025 | 38 | 0.730 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 24 | 0.720 |
Why?
| | Tissue Donors | 1 | 2025 | 425 | 0.690 |
Why?
| | Podocytes | 4 | 2026 | 80 | 0.680 |
Why?
| | Precision Medicine | 1 | 2025 | 462 | 0.670 |
Why?
| | Autoantibodies | 11 | 2026 | 1500 | 0.660 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 24 | 0.660 |
Why?
| | Cardiolipins | 1 | 2021 | 83 | 0.650 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3926 | 0.640 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 447 | 0.640 |
Why?
| | Cyclosporine | 3 | 2019 | 256 | 0.580 |
Why?
| | Otitis Media | 5 | 2016 | 178 | 0.570 |
Why?
| | Vascular System Injuries | 1 | 2019 | 79 | 0.570 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 8 | 0.570 |
Why?
| | Biomedical Research | 2 | 2025 | 729 | 0.570 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 81 | 0.560 |
Why?
| | Transplantation, Homologous | 4 | 2025 | 416 | 0.550 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.550 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 104 | 0.540 |
Why?
| | Doxorubicin | 5 | 2026 | 416 | 0.540 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 444 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 992 | 0.500 |
Why?
| | B-Lymphocytes | 7 | 2022 | 887 | 0.490 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 370 | 0.480 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 640 | 0.480 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 101 | 0.470 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 96 | 0.470 |
Why?
| | Renal Insufficiency | 1 | 2018 | 173 | 0.460 |
Why?
| | Peptide Fragments | 1 | 2019 | 693 | 0.440 |
Why?
| | Graft Survival | 5 | 2025 | 523 | 0.440 |
Why?
| | Male | 53 | 2026 | 73396 | 0.440 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 187 | 0.440 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1244 | 0.430 |
Why?
| | Complement C3a | 4 | 2024 | 40 | 0.420 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 27 | 0.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1432 | 0.410 |
Why?
| | Liver Neoplasms | 1 | 2020 | 776 | 0.400 |
Why?
| | Female | 48 | 2026 | 79499 | 0.400 |
Why?
| | Pregnancy Complications | 3 | 2018 | 609 | 0.400 |
Why?
| | Metabolomics | 5 | 2025 | 738 | 0.390 |
Why?
| | Allografts | 3 | 2025 | 151 | 0.380 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 611 | 0.380 |
Why?
| | Signal Transduction | 11 | 2026 | 5246 | 0.380 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 6 | 0.370 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 83 | 0.360 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 276 | 0.360 |
Why?
| | Immunity, Humoral | 1 | 2013 | 121 | 0.360 |
Why?
| | Autoimmunity | 5 | 2022 | 925 | 0.350 |
Why?
| | Liver | 2 | 2020 | 1864 | 0.350 |
Why?
| | Molecular Imaging | 1 | 2012 | 58 | 0.350 |
Why?
| | Complement C1q | 3 | 2014 | 33 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 846 | 0.340 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 125 | 0.340 |
Why?
| | Complement C2 | 2 | 2011 | 8 | 0.330 |
Why?
| | Oxidative Stress | 8 | 2024 | 1369 | 0.330 |
Why?
| | Blotting, Western | 7 | 2016 | 1177 | 0.310 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 277 | 0.310 |
Why?
| | CD55 Antigens | 3 | 2020 | 31 | 0.310 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 24 | 0.310 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 78 | 0.310 |
Why?
| | Cell Membrane | 4 | 2022 | 701 | 0.300 |
Why?
| | Disease Susceptibility | 2 | 2020 | 339 | 0.300 |
Why?
| | Nanoparticles | 2 | 2013 | 523 | 0.300 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 37 | 0.300 |
Why?
| | Prognosis | 6 | 2025 | 4351 | 0.300 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 745 | 0.290 |
Why?
| | Protozoan Proteins | 3 | 1998 | 88 | 0.290 |
Why?
| | Adult | 15 | 2026 | 41087 | 0.290 |
Why?
| | Properdin | 2 | 2020 | 9 | 0.280 |
Why?
| | Cytokines | 5 | 2019 | 2081 | 0.280 |
Why?
| | Kidney Function Tests | 2 | 2025 | 156 | 0.280 |
Why?
| | Antibody Specificity | 2 | 2021 | 181 | 0.280 |
Why?
| | Diarrhea | 1 | 2009 | 190 | 0.270 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.270 |
Why?
| | Complement C4 | 5 | 2021 | 31 | 0.270 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 150 | 0.270 |
Why?
| | Uremia | 2 | 2021 | 15 | 0.260 |
Why?
| | Complement C4b-Binding Protein | 2 | 2026 | 4 | 0.260 |
Why?
| | Cell Line | 7 | 2025 | 2814 | 0.260 |
Why?
| | Phagocytosis | 4 | 2023 | 298 | 0.260 |
Why?
| | Disease Progression | 6 | 2025 | 2867 | 0.260 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 80 | 0.260 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.260 |
Why?
| | Blood Platelets | 2 | 2024 | 382 | 0.260 |
Why?
| | Tandem Mass Spectrometry | 4 | 2025 | 576 | 0.250 |
Why?
| | Chemokines, CXC | 1 | 2007 | 68 | 0.250 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 127 | 0.250 |
Why?
| | Adaptive Immunity | 2 | 2019 | 173 | 0.240 |
Why?
| | Cells, Cultured | 6 | 2019 | 4118 | 0.240 |
Why?
| | Immunity, Innate | 7 | 2025 | 844 | 0.240 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 141 | 0.240 |
Why?
| | Flow Cytometry | 4 | 2022 | 1163 | 0.230 |
Why?
| | Middle Aged | 13 | 2026 | 36619 | 0.230 |
Why?
| | Tacrolimus | 3 | 2025 | 192 | 0.230 |
Why?
| | Chemokines | 1 | 2007 | 217 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1712 | 0.230 |
Why?
| | Phosphatidylethanolamines | 1 | 2026 | 78 | 0.230 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 217 | 0.230 |
Why?
| | Immune System Diseases | 1 | 2006 | 43 | 0.220 |
Why?
| | Protein Binding | 6 | 2019 | 2244 | 0.220 |
Why?
| | NF-kappa B | 3 | 2016 | 674 | 0.220 |
Why?
| | Organ Specificity | 3 | 2020 | 307 | 0.220 |
Why?
| | Rats | 9 | 2024 | 5586 | 0.220 |
Why?
| | Pilot Projects | 3 | 2021 | 1888 | 0.220 |
Why?
| | Biopsy | 3 | 2019 | 1075 | 0.220 |
Why?
| | Proteinuria | 4 | 2026 | 103 | 0.220 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 26 | 0.220 |
Why?
| | Caspases | 1 | 2006 | 233 | 0.220 |
Why?
| | Child | 12 | 2025 | 22693 | 0.210 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 29 | 0.210 |
Why?
| | Fetal Death | 1 | 2005 | 59 | 0.210 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 22 | 0.210 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 453 | 0.200 |
Why?
| | Platelet Activation | 1 | 2024 | 99 | 0.200 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 41 | 0.200 |
Why?
| | Membrane Glycoproteins | 2 | 2026 | 495 | 0.200 |
Why?
| | Macular Degeneration | 3 | 2012 | 196 | 0.200 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 11 | 0.190 |
Why?
| | Transplant Recipients | 1 | 2025 | 177 | 0.190 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 37 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 115 | 0.180 |
Why?
| | Ischemia | 3 | 2015 | 421 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2021 | 3647 | 0.180 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 228 | 0.170 |
Why?
| | Apoptosis | 2 | 2011 | 2439 | 0.170 |
Why?
| | CD59 Antigens | 3 | 2011 | 20 | 0.170 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 82 | 0.170 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 32 | 0.170 |
Why?
| | Myoglobin | 1 | 2021 | 13 | 0.170 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 13 | 0.170 |
Why?
| | Proteomics | 4 | 2018 | 1203 | 0.170 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 568 | 0.170 |
Why?
| | Immune System | 1 | 2022 | 181 | 0.170 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 32 | 0.160 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 57 | 0.160 |
Why?
| | Glutamic Acid | 1 | 2023 | 255 | 0.160 |
Why?
| | Frozen Sections | 1 | 2021 | 23 | 0.160 |
Why?
| | Paraffin Embedding | 1 | 2021 | 33 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 487 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2024 | 1957 | 0.160 |
Why?
| | Albuminuria | 2 | 2015 | 190 | 0.160 |
Why?
| | Formaldehyde | 1 | 2021 | 66 | 0.160 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 21 | 0.160 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 24 | 0.160 |
Why?
| | Staining and Labeling | 1 | 2021 | 148 | 0.160 |
Why?
| | Up-Regulation | 3 | 2019 | 841 | 0.150 |
Why?
| | Dendritic Cells | 2 | 2022 | 509 | 0.150 |
Why?
| | Lung | 6 | 2024 | 4122 | 0.150 |
Why?
| | Aged | 8 | 2021 | 26432 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 176 | 0.150 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 15 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 545 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 172 | 0.150 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 165 | 0.150 |
Why?
| | Urinalysis | 1 | 2019 | 82 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2021 | 11821 | 0.140 |
Why?
| | T-Lymphocytes | 5 | 2022 | 2012 | 0.140 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 139 | 0.140 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.140 |
Why?
| | North America | 1 | 2019 | 300 | 0.140 |
Why?
| | Complement C5 | 3 | 2020 | 33 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 908 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 974 | 0.140 |
Why?
| | Sepsis | 2 | 2016 | 669 | 0.140 |
Why?
| | Adolescent | 8 | 2025 | 22557 | 0.140 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 14 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2921 | 0.130 |
Why?
| | Granulocytes | 2 | 2016 | 82 | 0.130 |
Why?
| | Organelles | 1 | 1998 | 53 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2020 | 208 | 0.130 |
Why?
| | HLA Antigens | 1 | 2019 | 241 | 0.130 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 23 | 0.130 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.130 |
Why?
| | Gene Expression | 6 | 2017 | 1463 | 0.130 |
Why?
| | Cyclophilins | 1 | 2017 | 40 | 0.130 |
Why?
| | Brain Injuries | 3 | 2007 | 499 | 0.130 |
Why?
| | Erythrocytes | 2 | 2020 | 750 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 13 | 0.120 |
Why?
| | Brachial Artery | 1 | 2018 | 207 | 0.120 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.120 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 861 | 0.120 |
Why?
| | Liraglutide | 1 | 2016 | 32 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2022 | 1982 | 0.120 |
Why?
| | Interferon-beta | 2 | 2007 | 90 | 0.120 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 142 | 0.120 |
Why?
| | Bleomycin | 1 | 2018 | 255 | 0.120 |
Why?
| | Cell Aggregation | 1 | 2016 | 18 | 0.120 |
Why?
| | Sulfonylurea Compounds | 1 | 2016 | 49 | 0.120 |
Why?
| | Insulin, Long-Acting | 1 | 2016 | 65 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 81 | 0.120 |
Why?
| | Blood Pressure | 1 | 2003 | 1765 | 0.120 |
Why?
| | Phenols | 1 | 2017 | 106 | 0.120 |
Why?
| | Ear, Middle | 3 | 2012 | 78 | 0.120 |
Why?
| | Collagen Type VII | 3 | 2018 | 25 | 0.120 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.110 |
Why?
| | MicroRNAs | 1 | 2022 | 699 | 0.110 |
Why?
| | Tuberculosis | 1 | 2019 | 290 | 0.110 |
Why?
| | Interferon-alpha | 2 | 2007 | 201 | 0.110 |
Why?
| | Carboxypeptidases | 1 | 2015 | 12 | 0.110 |
Why?
| | Inflammation Mediators | 3 | 2019 | 508 | 0.110 |
Why?
| | Immunoprecipitation | 1 | 2016 | 150 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1064 | 0.110 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 325 | 0.110 |
Why?
| | Macrophages | 3 | 2013 | 1532 | 0.110 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5439 | 0.110 |
Why?
| | Mitochondria | 2 | 2024 | 997 | 0.110 |
Why?
| | Mucin-5B | 1 | 2018 | 234 | 0.110 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 30 | 0.110 |
Why?
| | Analysis of Variance | 2 | 2010 | 1298 | 0.110 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.110 |
Why?
| | Prospective Studies | 4 | 2023 | 8123 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 103 | 0.110 |
Why?
| | Vaccinia virus | 1 | 2015 | 35 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 441 | 0.110 |
Why?
| | Vasodilation | 1 | 2018 | 519 | 0.110 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 5 | 0.110 |
Why?
| | Ultrasonography | 1 | 2018 | 788 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1361 | 0.100 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.100 |
Why?
| | Hypertension | 1 | 2003 | 1272 | 0.100 |
Why?
| | Eustachian Tube | 1 | 2014 | 9 | 0.100 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 120 | 0.100 |
Why?
| | Edema | 1 | 2015 | 131 | 0.100 |
Why?
| | Fibroblasts | 1 | 2020 | 1034 | 0.100 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 209 | 0.100 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.100 |
Why?
| | Models, Immunological | 2 | 2012 | 100 | 0.100 |
Why?
| | Immunoglobulins | 2 | 2020 | 162 | 0.100 |
Why?
| | Neutrophils | 2 | 2013 | 1133 | 0.100 |
Why?
| | Mast Cells | 1 | 2015 | 150 | 0.100 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.100 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 72 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 340 | 0.100 |
Why?
| | Cricetulus | 2 | 2010 | 115 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 117 | 0.100 |
Why?
| | CHO Cells | 2 | 2010 | 167 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 416 | 0.100 |
Why?
| | Cricetinae | 2 | 2010 | 296 | 0.090 |
Why?
| | Serum | 1 | 2013 | 58 | 0.090 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 87 | 0.090 |
Why?
| | Genotype | 1 | 2018 | 1879 | 0.090 |
Why?
| | Recurrence | 1 | 2016 | 1133 | 0.090 |
Why?
| | Metformin | 1 | 2016 | 328 | 0.090 |
Why?
| | Genetic Variation | 1 | 2018 | 996 | 0.090 |
Why?
| | Acute Disease | 3 | 2014 | 1038 | 0.090 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.090 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 135 | 0.090 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1137 | 0.090 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 171 | 0.090 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 66 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2016 | 729 | 0.090 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 377 | 0.090 |
Why?
| | Skin | 2 | 2015 | 701 | 0.090 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 376 | 0.090 |
Why?
| | Amino Acids | 1 | 2016 | 515 | 0.090 |
Why?
| | Rhadinovirus | 1 | 2012 | 20 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 282 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 51 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 663 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 312 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 208 | 0.090 |
Why?
| | Pregnancy | 4 | 2018 | 7230 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 104 | 0.080 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 544 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2011 | 38 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1150 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 503 | 0.080 |
Why?
| | Down-Regulation | 4 | 2020 | 614 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 147 | 0.080 |
Why?
| | Tissue Distribution | 3 | 2019 | 334 | 0.080 |
Why?
| | Plasma Exchange | 1 | 2010 | 18 | 0.080 |
Why?
| | Risk Factors | 1 | 2025 | 10921 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 120 | 0.080 |
Why?
| | Blister | 2 | 2008 | 38 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 697 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 927 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1503 | 0.080 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 38 | 0.080 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 14 | 0.080 |
Why?
| | Opsonin Proteins | 1 | 2010 | 19 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2013 | 399 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 90 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 83 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2015 | 1135 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 54 | 0.070 |
Why?
| | Microbial Viability | 1 | 2010 | 83 | 0.070 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 366 | 0.070 |
Why?
| | Antibody Formation | 1 | 2010 | 290 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 404 | 0.070 |
Why?
| | Osteoarthritis | 1 | 2011 | 206 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2010 | 249 | 0.070 |
Why?
| | Image Enhancement | 1 | 2010 | 198 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7109 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 390 | 0.070 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1247 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2022 | 2791 | 0.070 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 13 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2786 | 0.070 |
Why?
| | Liver Regeneration | 1 | 2008 | 41 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 59 | 0.060 |
Why?
| | Cattle | 2 | 2026 | 940 | 0.060 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 35 | 0.060 |
Why?
| | Bacteremia | 1 | 2010 | 218 | 0.060 |
Why?
| | Hemolysis | 2 | 2020 | 242 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1036 | 0.060 |
Why?
| | Binding Sites | 3 | 2016 | 1309 | 0.060 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 41 | 0.060 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 76 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1792 | 0.060 |
Why?
| | Neurons | 2 | 2006 | 1668 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 2017 | 526 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2488 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1412 | 0.060 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 14330 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 58 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 199 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2006 | 90 | 0.060 |
Why?
| | Leukocytes | 1 | 2008 | 301 | 0.060 |
Why?
| | Integrin beta1 | 1 | 2026 | 31 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 883 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 155 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2134 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 7 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 172 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 778 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 461 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 588 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2537 | 0.050 |
Why?
| | Basement Membrane | 1 | 2005 | 33 | 0.050 |
Why?
| | Probability | 1 | 2006 | 309 | 0.050 |
Why?
| | Random Allocation | 1 | 2006 | 366 | 0.050 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 154 | 0.050 |
Why?
| | Child, Preschool | 3 | 2025 | 11913 | 0.050 |
Why?
| | Aristolochic Acids | 1 | 2024 | 1 | 0.050 |
Why?
| | Placental Insufficiency | 1 | 2006 | 126 | 0.050 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4093 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2005 | 61 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 176 | 0.050 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 146 | 0.050 |
Why?
| | Schistosoma | 1 | 2024 | 29 | 0.050 |
Why?
| | Lung Transplantation | 1 | 2007 | 326 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2675 | 0.050 |
Why?
| | Schistosomiasis | 1 | 2024 | 54 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1130 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3347 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 460 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 193 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 395 | 0.050 |
Why?
| | Drinking Behavior | 1 | 2003 | 15 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 371 | 0.050 |
Why?
| | Compulsive Behavior | 1 | 2003 | 6 | 0.050 |
Why?
| | Brain | 2 | 2006 | 2991 | 0.050 |
Why?
| | Myocardium | 1 | 2009 | 948 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 2 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 25 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 37 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 53 | 0.050 |
Why?
| | Lung Injury | 1 | 2006 | 263 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 53 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 371 | 0.050 |
Why?
| | Folic Acid | 1 | 2024 | 197 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 224 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 226 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 68 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2240 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 196 | 0.040 |
Why?
| | Carrier Proteins | 2 | 2003 | 728 | 0.040 |
Why?
| | Methionine | 1 | 2023 | 160 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2019 | 930 | 0.040 |
Why?
| | Neutralization Tests | 2 | 2015 | 74 | 0.040 |
Why?
| | Cartilage, Articular | 1 | 2006 | 366 | 0.040 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 36 | 0.040 |
Why?
| | Drug Combinations | 2 | 2016 | 400 | 0.040 |
Why?
| | HLA-D Antigens | 1 | 2022 | 30 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2623 | 0.040 |
Why?
| | Metabolome | 1 | 2025 | 390 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 252 | 0.040 |
Why?
| | Ubiquitination | 1 | 2022 | 119 | 0.040 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 77 | 0.040 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.040 |
Why?
| | Cholecalciferol | 1 | 2021 | 60 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2022 | 209 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2092 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 38 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 592 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 137 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 365 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 198 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 386 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 97 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 610 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 106 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 951 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 23 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 51 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 83 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 198 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 294 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 158 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 642 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 175 | 0.030 |
Why?
| | Brefeldin A | 1 | 1998 | 8 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3545 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2020 | 397 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 335 | 0.030 |
Why?
| | Cyclopentanes | 1 | 1998 | 17 | 0.030 |
Why?
| | Immunity, Active | 1 | 1998 | 8 | 0.030 |
Why?
| | Cell Compartmentation | 1 | 1998 | 51 | 0.030 |
Why?
| | A549 Cells | 1 | 2018 | 76 | 0.030 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 27 | 0.030 |
Why?
| | Parasitemia | 1 | 1998 | 15 | 0.030 |
Why?
| | Aotidae | 1 | 1998 | 11 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 384 | 0.030 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 48 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 27 | 0.030 |
Why?
| | Macrolides | 1 | 1998 | 68 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 69 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 402 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 678 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 382 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 134 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 98 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 170 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1224 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 202 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 67 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 69 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 106 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 22 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 439 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 213 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 311 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 127 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 149 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 34 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 925 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 70 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 26 | 0.030 |
Why?
| | Infant | 1 | 2009 | 10114 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 84 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 245 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 212 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 237 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 207 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 800 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 266 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 930 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 725 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 37 | 0.020 |
Why?
| | Water Deprivation | 2 | 2003 | 5 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2838 | 0.020 |
Why?
| | HeLa Cells | 1 | 2015 | 636 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1242 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 290 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2107 | 0.020 |
Why?
| | Pyridones | 1 | 2015 | 210 | 0.020 |
Why?
| | Drug Synergism | 1 | 2014 | 354 | 0.020 |
Why?
| | International Cooperation | 1 | 2013 | 193 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 119 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2219 | 0.020 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 61 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 109 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 385 | 0.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 162 | 0.020 |
Why?
| | Coinfection | 1 | 2014 | 143 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 78 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.020 |
Why?
| | Hypoxia | 1 | 2020 | 1211 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1053 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 25 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 175 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 69 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2016 | 490 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2070 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 187 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 377 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 371 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 451 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 173 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 174 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 279 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 689 | 0.020 |
Why?
| | Joints | 1 | 2011 | 107 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 342 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 471 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 103 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 295 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 198 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 177 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 627 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 404 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 297 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1378 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 241 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 477 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 536 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 426 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 267 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1041 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 834 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1031 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 55 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 29 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 87 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 166 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 87 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 23 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 907 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 142 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1942 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 752 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2123 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 380 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 20 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 60 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 63 | 0.010 |
Why?
| | Methacholine Chloride | 1 | 2006 | 50 | 0.010 |
Why?
| | Protein Transport | 1 | 2008 | 443 | 0.010 |
Why?
| | Vaccination | 1 | 2015 | 1449 | 0.010 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 49 | 0.010 |
Why?
| | fas Receptor | 1 | 2006 | 91 | 0.010 |
Why?
| | Blood Glucose | 1 | 2016 | 2360 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 74 | 0.010 |
Why?
| | Trachea | 1 | 2007 | 253 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 115 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 230 | 0.010 |
Why?
| | Models, Molecular | 1 | 2010 | 1574 | 0.010 |
Why?
| | Synovial Membrane | 1 | 2006 | 130 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5899 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 310 | 0.010 |
Why?
| | Cell Death | 1 | 2006 | 379 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3416 | 0.010 |
Why?
| | Swine | 1 | 2006 | 821 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3206 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 538 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 20 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 28 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 329 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 992 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 165 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1105 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 531 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 784 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1761 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2599 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 101 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2022 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1215 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 1800 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 794 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2954 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 28 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 179 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 399 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|